GSK3B and Parkinson disease: These effects may be related to inhibition of GSK-3β activity by the tested agents, where inhibiting GSK-3β is suggested to have a protective effect on dopaminergic neurons against dopaminergic neurodegeneration by hampering the oxidative stress and promoting the increased expression of Bcl2, which abrogates the neuronal cell apoptosis associated with PD [59].